Biotech IPO news from FierceBiotech
NewsAnalysts predict more M&A as capital shrinks
A shortage of new money is likely to drive more and more life sciences companies into mergers and acquisitions, say some of the Read more...
Alimera Sciences files $75M IPO
Alimera Sciences is braving a badly roiled public market with plans to push a $75 million IPO. The Atlanta-based biotech is developing ophthalmic drugs. Credit Suisse, Citi, Cowen and Co. and Leerink Read more...
Emergent adds new space for biotech start-ups
Emergent Technologies Inc has doubled its office space, taking new digs in Austin that includes new laboratory space for the biotech companies that it helps foster. ETI specializes in creating new Read more...
Jazz Pharma axes staffers after delaying two trials
Jazz Pharmaceuticals says it needs to extend the development time line for two key drug programs, a move that triggered a decision to lay off 33 workers, or eight percent of its workforce. In a Read more...
Peplin joins list of developers to drop IPO
You can count Peplin on the growing roster of developers that couldn't make a go of an IPO. The Emeryville, CA-based company cited "unfavorable market conditions" as its reason for dropping the IPO, Read more...
Vertex shares rise on positive data for telaprevir
Vertex Pharmaceuticals saw a significant bump in its share price this morning after researchers released new, mid-stage interim data backing telaprevir for hepatitis C. The company is now penciling Read more...
SPOTLIGHT: Talecris may be sold
Almost a year after filing plans for a $1 billion IPO for Talecris Biotherapeutics, Cerberus and Read more...
Sonus, OncoGenex to merge
Bothell, WA-based Sonus Pharmaceuticals is merging with Canada's OncoGenex Technologies and will operate under the name OncoGenex Pharmaceuticals. OncoGenex's CEO Scott Cormack will head up the new Read more...
Emergent BioSolutions buys flu vaccine maker
Emergent BioSolutions has inked a deal to acquire the Protein Sciences Corporation assets for up to $75 million. The move is part of Emergent's strategy to expand its product portfolio with a drug Read more...
Early IPO at Aldagen leaves analysts wondering
A pair of analysts has taken a cautious attitude toward Aldagen's plans for an $80 million IPO. The stem-cell company has no Read more...
| Press ReleasesPRESS RELEASE: Xanodyne Pharmaceuticals Files to Go Public Xanodyne Pharmaceuticals Files to Go Public NEWPORT, Ky. -- Xanodyne Pharmaceuticals, Inc. announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission Read more... PRESS RELEASE: Anacor files IPO ANACOR FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING Palo Alto, Calif. – August 31, 2007 – Anacor Pharmaceuticals announced today that it has filed a registration statement on Form Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets